Skip to main content

Health Canada Clears Cepheid's MRSA Test to Combat Hospital Infections

NEW YORK (GenomeWeb News) – The Canadian government has licensed Cepheid’s test for methicillin-resistant Staphylococcus aureus for use in hospitals, the company said today.
The company said Health Canada’s device license for the Xpert MRSA test, which runs on the GeneXpert System and identifies MRSA in around 70 minutes, can help Canadian healthcare organizations maintain better control measures for MRSA hospital-acquired infections. 
A government committee in Ontario last year recommended that high-risk patients “should be actively screened for MRSA,” the company said. The rate of MRSA occurrence in Canadian hospitals has risen “steadily between 1995 and 2004,” Cepheid added in a statement.
“We expect to see more countries moving toward initiation of active surveillance programs," said Cepheid CEO John Bishop.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.